FMP
Artelo Biosciences, Inc.
ARTL
NASDAQ
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
1.31 USD
0.01 (0.763%)
About
ceo
Mr. Gregory D. Gorgas M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://www.artelobio.com
exchange
NASDAQ
Description
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences, Inc. has research collaboration with Trinity College Dublin to i...
CIK
0001621221
ISIN
US04301G5080
CUSIP
04301G201
Address
505 Lomas Santa Fe
Phone
858 925 7049
Country
US
Employee
6
IPO Date
Jun 21, 2019
Summary
CIK
0001621221
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
04301G201
ISIN
US04301G5080
Country
US
Price
1.31
Beta
1.2
Volume Avg.
15.01k
Market Cap
4.23M
Shares
-
52-Week
1.15-2.98
DCF
2.41
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.42
P/B
-
Website
https://www.artelobio.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ARTL News
It looks like there's no news available.
